$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Dynavax Technologies Corporation (NASDAQ: DVAX) related to its sale to Sanofi.

PRNewsWire • Jan 5, 2026

CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. The updated release reads: DYNAVAX INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale o.

Business Wire • Dec 30, 2025

Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire • Dec 31, 2025

Shareholder Alert: The Ademi Firm investigates whether DigitalBridge Group, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Dec. 29, 2025 /PRNewswire/ -- The Ademi Firm is investigating DigitalBridge (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with SoftBank. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Dec 29, 2025

Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying

Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the shingles vaccine market.

Investopedia • Dec 24, 2025

Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37%

Shares of Dynavax Technologies jumped sharply in premarket trading on Wednesday after the US vaccine maker agreed to be acquired by French pharmaceutical group Sanofi in an all-cash deal valued at about $2.2 billion. Sanofi said it will pay $15.

Invezz • Dec 24, 2025

Why Dynavax Stock Soared Today

Sanofi is launching an all-cash tender offer for Dynavax's shares. The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price.

The Motley Fool • Dec 24, 2025

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.

WSJ • Dec 24, 2025

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price on December 23, 2025 EMERYVILLE, Calif. , Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate.

PRNewsWire • Dec 24, 2025

Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Dec. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Dynavax (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Dec 24, 2025